Literature DB >> 25476420

Direct cellular delivery of human proteasomes to delay tau aggregation.

Dong Hoon Han1, Hee-Kyung Na2, Won Hoon Choi1, Jung Hoon Lee1, Yun Kyung Kim3, Cheolhee Won2, Seung-Han Lee1, Kwang Pyo Kim1, Jeff Kuret4, Dal-Hee Min2, Min Jae Lee1.   

Abstract

The 26S proteasome is the primary machinery that degrades ubiquitin (Ub)-conjugated proteins, including many proteotoxic proteins implicated in neurodegeneraton. It has been suggested that the elevation of proteasomal activity is tolerable to cells and may be beneficial to prevent the accumulation of protein aggregates. Here we show that purified proteasomes can be directly transported into cells through mesoporous silica nanoparticle-mediated endocytosis. Proteasomes that are loaded onto nanoparticles through non-covalent interactions between polyhistidine tags and nickel ions fully retain their proteolytic activity. Cells treated with exogenous proteasomes are more efficient in degrading overexpressed human tau than endogenous proteasomal substrates, resulting in decreased levels of tau aggregates. Moreover, exogenous proteasome delivery significantly promotes cell survival against proteotoxic stress caused by tau and reactive oxygen species. These data demonstrate that increasing cellular proteasome activity through the direct delivery of purified proteasomes may be an effective strategy for reducing cellular levels of proteotoxic proteins.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25476420     DOI: 10.1038/ncomms6633

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  31 in total

1.  Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling.

Authors:  Natura Myeku; Catherine L Clelland; Sheina Emrani; Nikolay V Kukushkin; Wai Haung Yu; Alfred L Goldberg; Karen E Duff
Journal:  Nat Med       Date:  2015-12-21       Impact factor: 53.440

Review 2.  The Proteasome and Oxidative Stress in Alzheimer's Disease.

Authors:  Vicent Bonet-Costa; Laura Corrales-Diaz Pomatto; Kelvin J A Davies
Journal:  Antioxid Redox Signal       Date:  2016-08-25       Impact factor: 8.401

3.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

Review 4.  Proteasome Biology: Chemistry and Bioengineering Insights.

Authors:  Lucia Račková; Erika Csekes
Journal:  Polymers (Basel)       Date:  2020-12-04       Impact factor: 4.329

Review 5.  It's all about tau.

Authors:  Cheril Tapia-Rojas; Fabian Cabezas-Opazo; Carol A Deaton; Erick H Vergara; Gail V W Johnson; Rodrigo A Quintanilla
Journal:  Prog Neurobiol       Date:  2018-12-31       Impact factor: 11.685

Review 6.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

7.  Changes in proteome solubility indicate widespread proteostatic disruption in mouse models of neurodegenerative disease.

Authors:  Michael C Pace; Guilian Xu; Susan Fromholt; John Howard; Keith Crosby; Benoit I Giasson; Jada Lewis; David R Borchelt
Journal:  Acta Neuropathol       Date:  2018-08-23       Impact factor: 17.088

8.  The arginylation branch of the N-end rule pathway positively regulates cellular autophagic flux and clearance of proteotoxic proteins.

Authors:  Yanxialei Jiang; Jeeyoung Lee; Jung Hoon Lee; Joon Won Lee; Ji Hyeon Kim; Won Hoon Choi; Young Dong Yoo; Hyunjoo Cha-Molstad; Bo Yeon Kim; Yong Tae Kwon; Sue Ah Noh; Kwang Pyo Kim; Min Jae Lee
Journal:  Autophagy       Date:  2016-08-25       Impact factor: 16.016

Review 9.  Nanotechnology for protein delivery: Overview and perspectives.

Authors:  Mikyung Yu; Jun Wu; Jinjun Shi; Omid C Farokhzad
Journal:  J Control Release       Date:  2015-10-13       Impact factor: 9.776

Review 10.  Aim for the core: suitability of the ubiquitin-independent 20S proteasome as a drug target in neurodegeneration.

Authors:  Kwadwo A Opoku-Nsiah; Jason E Gestwicki
Journal:  Transl Res       Date:  2018-06-19       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.